Cardiac Valve or Heart Valve allows blood to flow in only one direction through the heart. Human heart consists of four valves. These valves open and closes compulsory on differential blood pressure on each side. Main role is when blood enters the heart first passes through the tricuspid valve and then the pulmonary valve. After returning from the lungs, the blood passes through the mitral valve and exits via the aortic valve as heart valves are one-way valves. Global Cardiac Valve Market [SM1] is expected to grow at a CAGR of 11.5% during the forecast period.
Furthermore, valve replacement remains the most widely used technique but the proportion of valve repair procedures is increasing in experienced treatment centers. Moreover, increasing development in medical technology and its wide range of application used in the treatment of various cardiac diseases will fuel the growth of the market. However, high cost of the treatment likely to restrain the growth of the market over the assessment period.
Increasing number of people with cardiovascular diseases and increasing number of cardiac surgery have stimulated the growth of the market. Additionally, increasing incident of diabetes and obesity, adoption of deskbound lifestyle rising geriatric population, and excessive use of tobacco and alcohol projected to propel the growth of the market. On the other hand, high cost of treatment methods may hamper the growth of the global cardiac valve market over the forecast period.
Global Cardiac Valve Market – Key Players
Some of the key players in the global market:
- Edwards Lifesciences Corporation (U.S.)
- Boston Scientific Corporation (U.S.)
- St. Jude Medical, Inc. (an Abbott Laboratories Company) (U.S.)
- LivaNova PLC (U.K.)
- Symetis SA (Switzerland)
- Jenavalve Technology, Inc. (Germany)
- CryoLife, Inc. (U.S.)
- TTK HealthCare (India)
- Colibri Heart Valve, LLC (U.S.)
- Lepu Medical Technology Co., Ltd. (China)
- Braile Biomédica (Brazil)
Global Cardiac Valve Market – Competitive Analysis
June, 2017- Edwards Life sciences Corporation SAPIEN 3 Valve received FDA approval for Aortic, Mitral Valve-In-Valve Procedures. Expansion of the SAPIEN 3 device indication to include valve-in-valve procedures is a meaningful advancement for patients at high risk of an additional open-heart valve procedure, particularly for those in need of a safe alternative for mitral valve replacement. According to Edwards Life sciences Corporation company report this approval brings a safe and effective transcatheter therapy to patients who would do very poorly with repeat open-heart surgery
Get Sample Report @ https://www.marketresearchfuture.com/sample_request/560 .
March, 2017- Boston Scientific is acquired Swiss company Symetis, move made by the medical device giant to strengthen its portfolio of minimally invasive heart valve replacement products. Symetis makes heart products for transcatheter aortic valve replacement, a minimally invasive procedure that uses a catheter to deploy a valve that takes over for an old, damaged one. Moreover, company has commercialized two heart valve systems i.e the Acurate TA and the Acurate neo/TF valve. Both are sold in Europe and some other markets, but not the U.S. The company also has an investigational next generation valve system that is currently in clinical testing.
Dec, 2016- Boston Scientific acquired Neovasc advanced biological tissue capabilities. Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace, including the Tiara technology in development for the transcatheter treatment of mitral valve disease, and the Neovasc Reducer technology for the treatment of refractory angina. Neovasc advanced biological tissue capabilities had integrated into the Boston Scientific structural heart business for use in the manufacturing of the Lotus valve and future heart valve technologies.
August, 2015- Medtronic to acquired Twelve, Inc., developer of transcatheter mitral valve replacement device. Twelve, Inc., a privately held medical device company based in Redwood City, California, focuses on the development of a transcatheter mitral valve replacement (TMVR) device. This acquisition had strategically augmented existing capabilities in the transcatheter mitral space, which represents an important growth opportunity for Medtronic. Twelve’s technology is a truly creative solution that brings together valve technology with a unique and highly differentiated dual-stent fixation design.
Global Cardiac Valve Market – Segmentation
The Global Cardiac Valve Market is segmented on the basis of types, by diseases, by treatment, and by end users.
On the basis of types, the market is segmented into trans-catheter heart valve, tissue heart valve, mechanical heart valve, and others. On the basis of disease, the market is segmented into aortic valve replacement, heart valve disease, mitral valve stenosis, and others.
On the basis of treatments, it is segmented into valve replacement, valve repair, and others. On the basis of end users the market is segmented into cardiac research institute, hospital & clinics, and others.
To Know More Enquire @ https://www.marketresearchfuture.com/enquiry/560 .
Major Table of Content
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.2 Scope of the Study
2.2.1 Research Objective
Chapter 3. Research Methodology
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar